Business Overview: CONMED Corporation (NYSE: CNMD)

---

Executive Summary

CONMED Corporation is a global medical technology company headquartered in Largo, Florida, that designs, manufactures, and markets surgical devices and equipment used primarily in orthopedic and general surgery procedures. The company operates through two reportable segments \- Orthopedic Surgery and General Surgery \- and sells into more than 100 countries, with roughly a third of revenue generated internationally. CONMED's product portfolio spans sports medicine implants and instrumentation, powered surgical tools, advanced energy devices, insufflation and smoke evacuation systems, and single\-use surgical consumables, positioning it as a mid\-cap, diversified supplier to hospitals and ambulatory surgery centers competing against much larger strategic players.

For fiscal year 2025, CONMED generated consolidated net sales of approximately $1.375 billion, up 5.2% year\-over\-year, with Orthopedic Surgery contributing about 42% of revenue and General Surgery approximately 58%. The business is increasingly weighted toward high\-margin, single\-use recurring revenue \- roughly 78% of Orthopedic Surgery sales and 92% of General Surgery sales come from disposable products \- which supports a durable, procedure\-driven demand base less exposed to large lumpy capital equipment cycles. Adjusted diluted EPS grew to $4.59 in 2025 from $4.17 in 2024, even as GAAP diluted EPS fell sharply to $1.51 from $4.25, reflecting one\-time charges tied to portfolio restructuring.

The single most decision\-relevant current fact is CONMED's May 2026 announcement that it will exit its gastroenterology product line, a business that generated $90\-95 million of 2025 revenue at roughly 45% gross margins, in order to concentrate capital and management attention on minimally invasive surgery, smoke evacuation, and orthopedic soft\-tissue repair. Management expects the exit to dilute 2026 adjusted EPS by $0.45\-$0.55 per share while improving consolidated gross margin by approximately 80 basis points, with proceeds directed toward debt reduction and share repurchases \- a trade of near\-term earnings for a more focused, higher\-margin long\-term mix.

---

1. Core Business Model & How They Work

CONMED's business model is built on a "razor\-and\-blade" dynamic common to medical devices: the company places durable capital equipment (powered instrument consoles, energy generators, insufflation systems) with hospitals and surgery centers, then generates recurring, high\-margin revenue from the single\-use disposables, implants, and consumables required for every subsequent procedure. This structure gives CONMED visibility into a large installed base of procedural volume that recurs independent of new capital purchases, and it is reinforced by direct sales forces and clinical/physician education programs that build surgeon preference and switching friction around specific instrument platforms.

Key Operational Drivers

1. Recurring Single\-Use Revenue Mix \- Approximately 78% of Orthopedic Surgery and 92% of General Surgery revenue comes from disposable, repeat\-purchase products, providing a stable, procedure\-linked revenue base.
2. Direct Surgeon Engagement & Training \- Extensive physician education, cadaver labs, and clinical support build surgeon loyalty to specific technique platforms (e.g., BioBrace, AirSeal), raising the cost of switching to competing systems.
3. Portfolio Focus & Active Rationalization \- Management is actively pruning lower\-growth, lower\-margin lines (e.g., the 2026 gastroenterology exit) to concentrate R&D and sales investment on higher\-growth, higher\-margin platforms.
4. Global Direct and Distributor Sales Network \- A blended direct sales/distributor model across more than 100 countries supports international growth, which grew 7.4% as reported in 2025, faster than the 3.5% domestic growth rate.
5. Manufacturing Scale & Supply Chain Efficiency \- Ongoing investment in manufacturing productivity and cost discipline supports gradual gross margin expansion even amid input cost and tariff pressures.

---

2. Business Segments

Orthopedic Surgery (approximately 42% of 2025 revenue). This segment provides sports medicine solutions for knee, hip, shoulder, and other extremity procedures, including the BioBrace bio\-inductive implant platform, TruShot suture anchor and delivery systems, and powered surgical instruments marketed under the Hall brand. The segment competes against considerably larger orthopedic franchises at Smith & Nephew, Stryker, and Johnson & Johnson MedTech, and derives roughly 78% of its revenue from single\-use, recurring products such as sutures, anchors, and biologics.

General Surgery (approximately 58% of 2025 revenue). This segment covers advanced surgical and endoscopic technologies, anchored by the AirSeal valve\-free insufflation system, Buffalo Filter smoke evacuation products (acquired via the Buffalo Filter acquisition), advanced energy devices, and (through early 2026) gastroenterology endoscopy accessories. Approximately 92% of segment revenue is single\-use and recurring, and primary competitors include Medtronic, Boston Scientific, and Cook Medical. Following the 2026 exit from gastroenterology, this segment will be increasingly concentrated on minimally invasive surgery and smoke evacuation, its highest\-growth sub\-categories.

---

3. Product Portfolio

---

4. Competitive Landscape

CONMED competes against several of the largest medical device companies in the world, most of which have substantially greater scale, R&D budgets, and breadth of surgical platforms. In orthopedics, CONMED is a focused sports\-medicine and powered\-instrument player rather than a full\-line joint reconstruction competitor, allowing it to concentrate resources on soft\-tissue repair niches. In general surgery, its AirSeal and Buffalo Filter franchises hold differentiated positions in insufflation and smoke evacuation, categories where CONMED has built meaningful share against larger diversified competitors. The company's relatively smaller scale (roughly $1.4 billion in revenue versus tens of billions for its largest rivals) means it must compete on clinical differentiation, surgeon relationships, and focused innovation rather than broad portfolio bundling or global sales force scale.

Key Competitors:

• Stryker Corporation \- broad orthopedic, surgical, and powered instrument portfolio with substantially greater scale
• Medtronic plc \- diversified med\-tech giant competing in advanced energy and surgical technologies
• Johnson & Johnson MedTech \- major orthopedic and surgical device competitor with extensive distribution reach
• Smith & Nephew / Boston Scientific / Cook Medical \- category\-specific competitors in sports medicine, endoscopy, and GI devices respectively

CONMED's ability to defend share against these larger players rests on maintaining clinical differentiation in its focused categories and continuing to shift its mix toward recurring, single\-use revenue that competitors' capital equipment sales cycles do not as directly threaten.

---

5. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• High mix of recurring, single\-use disposable revenue (78\-92% by segment) that provides revenue stability tied to procedure volumes rather than lumpy capital purchases.
• Differentiated, clinically validated platforms (AirSeal, BioBrace, Buffalo Filter) that have built genuine surgeon and OR staff preference in their niches.
• Active portfolio management discipline, demonstrated by the 2026 gastroenterology exit, that reallocates capital toward higher\-growth, higher\-margin categories.
• Established direct sales and physician\-education infrastructure that raises switching costs for surgeons trained on CONMED's specific instrumentation and techniques.

Strategic Risks & Vulnerabilities

1. Significant scale disadvantage versus giants like Stryker, Medtronic, and J&J MedTech, who can outspend CONMED on R&D, M&A, and sales force expansion.
2. Elevated leverage, with total debt of roughly $833 million against a debt\-to\-equity ratio near 80% and operating cash flow covering only a modest share of total debt, constraining financial flexibility.
3. Near\-term EPS dilution and execution risk from the gastroenterology exit, which removes $90\-95 million of revenue and pressures 2026 adjusted EPS by an estimated $0.45\-$0.55 per share.
4. Exposure to hospital capital spending cycles, tariff and input\-cost pressures, and pricing pressure from larger competitors bundling broader portfolios with health systems.

---

6. Financial Overview

---

7. Summary Conclusion

CONMED occupies a focused, mid\-cap niche within the medical device industry, competing effectively in sports medicine soft\-tissue repair and minimally invasive general surgery despite facing much larger, better\-capitalized rivals in Stryker, Medtronic, and Johnson & Johnson MedTech. Its high mix of recurring single\-use revenue and differentiated platforms like AirSeal and BioBrace provide a reasonably durable, procedure\-linked earnings base, and management's willingness to exit the lower\-margin, slower\-growth gastroenterology business signals a disciplined effort to concentrate capital on its strongest franchises. That strategic sharpening comes with near\-term costs, however: 2026 EPS dilution from the GI exit and an elevated debt load that leaves less room for error. Investors should watch execution on margin expansion post\-divestiture and progress on deleveraging as the key near\-term catalysts for whether CONMED's narrower, more focused portfolio translates into sustainably improved profitability.